

## 19th Kumamoto AIDS seminar

1<sup>st</sup>

November 6th, Tuesday

Kumamoto Kenmin Koryu Kaikan Parea 10F Parea Hall 11:20-18:10

10:30 -11:20				Registration & Poster hanging up	
11:20 -11:30		Opening Remarks		*Special Remarks	Shinji Harada [President, Kumamoto University]
Session I		New approaches to HIV virology		11:30-13:10 [100] Chairs: Mark Brockman (Simon Fraser Univ.) & Takamasa Ueno (Kumamoto Univ.)	
11:30-12:00 [30]	O - 01	<b>Constantinos Petrovas</b> National Institute of Health, USA	Lymph Node Dynamics in HIV/SIV: what can we learn from imaging studies?		
12:00-12:15 [15]	O - 02	<b>Xiaoming Sun</b> Harvard Medical School, USA	A systems biology approach to dissecting the HIV-1 immune control in Elite Controllers		
12:15-12:40 [25]	O - 03	<b>Yorifumi Satou</b> Kumamoto University, Japan	Selection of HIV-1 proviruses under combined treatment with LRA and an anti-retroviral drug in vitro		
12:40-13:10 [30]	O - 04	<b>Zabrina Brumme</b> BC Centre for Excellence in HIV/AIDS, Canada	Using phylogenetics to reveal new insights into latent HIV reservoir dynamics and persistence		
Session II				9F Meeting Room	
Poster Discussion with light meal (Best Poster vote)				13:10-15:00 (110) Chairs: Yorifumi Satou (Kumamoto Univ.), Seiji Okada(Kumamoto Univ.) Naoki Ishizuka (Cancer Institute Hospital/Kumamoto Univ.)	
Session III		Abstract-driven session		15:00-15:50 [50] Chairs: Yosuke Maeda (Kumamoto Univ.) & Kazuhisa Yoshimura (Sakura Hosp./Kumamoto Univ.)	
15:00-15:10 [10]	O - 05 (P-08)	<b>Takuya Kobayakawa</b> Tokyo Medical and Dental University, Japan	Structure-activity relationship studies of CD4 mimic molecules for targeting an envelope protein gp120 on HIV-1		
15:10-15:20 [10]	O - 06 (P-22)	<b>Win Thida</b> Kumamoto University, Japan	ADCC activity of HIV-1 Env-specific monoclonal antibodies against subtype B and CRF01_AE viruses from Japan and Vietnam		
15:20-15:30 [10]	O - 07 (P-07)	<b>Tomohiro Kanuma</b> National Institutes of Biomedical Innovation, Health and Nutrition, Japan	STING ligands induce re-activation of latently SIV-infected cells and augment SIV-specific CTL responses		
15:30-15:40 [10]	O - 08 (P-31)	<b>Jutatip Panaampon</b> Kumamoto University, Japan	Effect of Elotuzumab (Anti-CS1 Antibody) on NK cells mediated cytotoxicity against primary effusion lymphoma		
15:40-15:50 [10]	O - 09 (P-12)	<b>Osamu Noyori</b> Kumamoto University, Japan	Virological and hematological analyses of fibrocytes in HIV-1 infected patients		
15:50-16:10 [20]		Coffee Break			
Session IV		Human cellular immune response		16:10-17:25 [75] Chairs: Tetsuro Matano (NIID/Kumamoto Univ.) & Hiroyuki Gatanaga (ACC/Kumamoto Univ.)	
16:10-16:25 [15]	O - 10	<b>Takayuki Chikata</b> Kumamoto University, Japan	Identification and characterization of HIV-1 epitopes presented by the protective HLA-C*12:02 allele using mass spectrometry analysis of single-allele transfectants.		
16:25-16:55 [30]	O - 11	<b>Katsumi Maenaka</b> Hokkaido University, Japan	Structural basis for immune regulation of HIV: Nef and Killer cell Ig-like receptors		
16:55-17:25 [30]	O - 12	<b>Masafumi Takiguchi</b> Kumamoto University, Japan	CTL- and NK cell-mediated HIV-1 control in Asians		
Session V		Key Note		17:25-18:10 [45] Chair: Masafumi Takiguchi (Kumamoto Univ.)	
17:25-18:10 [45]	O - 13	<b>Andrew McMichael</b> University of Oxford, U.K	Can vaccine-stimulated T cell immune responses prevent HIV-1 infection?		
19:00-21:00 [120]		Reception in Nikko Hotel 5F			

2<sup>nd</sup>

November 7th, Wednesday

8:45 Registration

Kumamoto Kenmin Koryu Kaikan Parea 10F Parea Hall 9:00-13:10

Session VI Persistent viral infections		9:00-10:00 [60]	
Chairs: Masao Matsuoka (Kumamoto Univ.) & Kenji Maeda (NCGM, Japan)			
09:00-09:30 [30]	O - 14	<b>Masanori Ikeda</b> Kagoshima University, Japan	Clofarabine exhibits bifunctional anti-Hepatoma virus activity
09:30-9:45 [15]	O - 15	<b>Paola Miyazato</b> Kumamoto University, Japan	Possible role of ZC3HAV1 protein in the post-transcriptional regulation of HTLV-1 RNAs
9:45-10:00 [15]	O - 16	<b>Yusuke Higuchi</b> Kyoto University, Japan	Loss of IL-6 accelerates inflammation and lymphomagenesis in HTLV-1 bZIP factor transgenic mice
Session VII Epidemiology and co-infection		10:00-10:50 [50]	
Chairs: Shinichi Oka (NCGM/Kumamoto Univ.) & Shuzo Matsushita (Kumamoto Univ.)			
10:00-10:10 [10]	O - 17 (P-03)	<b>Godfrey Barabona</b> Kumamoto University, Japan	Accumulated HIV-1 drug resistance restrict therapeutic options in Tanzania
10:10-10:20 [10]	O - 18 (P-04)	<b>Daisuke Shiojiri</b> ACC/Kumamoto University, Japan	Risk factors associated with anorectal HPV infection and HPV precancer in HIV-non-infected and HIV-infected Men who have Sex with Men
10:20-10:50 [30]	O - 19	<b>Sarah Rowland Jones</b> University of Oxford, UK/Kumamoto University, Japan	High cytomegalovirus (CMV) DNA-aemia is associated with stunting and chronic lung disease in older children with perinatally-acquired HIV infection (PHIV)
10:50-11:10 [20] Coffee Break			
Session VIII Intrinsic inhibitors for HIV-1		11:10-11:55 [45]	
Chairs: Shogo Misumi (Kumamoto Univ.) & Shinya Suzu (Kumamoto Univ.)			
11:10-11:20 [10]	O - 20 (P-17)	<b>Naoki Kishimoto</b> Kumamoto University, Japan	Bifunctional inhibitory effects of alpha-enolase on HIV-1 replication
11:20-11:30 [10]	O - 21 (P-14)	<b>Omnia AbdelRahman</b> Kumamoto University, Japan	Mechanisms of anti-HIV-1 activity of IL-32 in macrophages
11:30-11:55 [25]	O - 22	<b>Yasuo Ariumi</b> Kumamoto University, Japan	Apolipoprotein E is an HIV-1-inducible inhibitor of viral production and infectivity in macrophages
Session IX Monkey model		11:55-13:10 [75]	
Chairs: Takeo Kuwata (Kumamoto Univ.) & Takuya Yamamoto (NIBIOHN/Kumamoto Univ.)			
11:55-12:25 [30]	O - 23	<b>David Watkins</b> University of Miami, USA	Neutralizing monoclonal antibodies to prevent and treat yellow fever virus infection
12:25-12:40 [15]	O - 24	<b>Takushi Nomura</b> National Institute of Infectious Diseases, Japan	Gag epitope-specific CD8+ T cell responses in SIV controllers
12:40-13:10 [30]	O - 25	<b>Yoshinori Fukazawa</b> Oregon Health & Science University, USA	Potential to prevent or delay AIDS virus rebound by early antiretroviral therapy
13:10	Concluding Remarks		<b>Andrew McMichael (University of Oxford, U.K)</b>